Sign In
Buy OPT
$3.41
+0 (+0%)
At Close: Jun 30, 2025
Outlook Therapeutics Stock Sinks After FDA Rejects Eye Drug Again
08:18am, Friday, 02'nd Jan 2026
Outlook Therapeutics' stock fell to a new low due to FDA rejection of its Lytenava filing for wet AMD. Efficacy evidence remains key issue.
Novogen (NASDAQ:KZIA) & Opthea (NASDAQ:OPT) Head to Head Analysis
05:12am, Tuesday, 23'rd Dec 2025
Novogen (NASDAQ: KZIA - Get Free Report) and Opthea (NASDAQ: OPT - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based o
Opthea (NASDAQ:OPT) Stock Price Up 7.2% – Here’s What Happened
02:30am, Tuesday, 18'th Nov 2025
Opthea Limited Unsponsored ADR (NASDAQ: OPT - Get Free Report) rose 7.2% on Monday. The company traded as high as $3.48 and last traded at $3.41. Approximately 3,000 shares traded hands during trading
Opthea Provides Corporate Update
07:00pm, Monday, 18'th Aug 2025
Successful DFA settlement reached Company with cash and cash equivalents of approximately USD20M Dr Fred Guerard, CEO, Tom Reilly, CFO, and Sujal Shah, Director, to step down Dr Jeremy Levin to contin
Opthea Announces Decision to Discontinue Wet AMD Trials
12:01am, Monday, 31'st Mar 2025
ShORe Phase 3 topline results accelerated; trial did not meet primary endpoint of mean change in BCVA from baseline to week 52
Opthea Announces COAST Phase 3 Trial Topline Results
12:01am, Monday, 24'th Mar 2025
COAST Phase 3 trial failed to meet primary endpoint of mean change in BCVA from baseline to week 52 Opthea considering impact of negative trial results under its Development Funding Agreement and on t
Opthea Announces Phase 2b Wet AMD Publication
07:00am, Monday, 03'rd Mar 2025
Baseline angiographic lesion characteristics predictive of clinical response Published in peer-reviewed journal Ophthalmic Surgery, Lasers and Imaging Retina MELBOURNE, Australia and PRINCETON, N.J.,
Opthea to Present at Oppenheimer Healthcare Conference
07:00am, Friday, 07'th Feb 2025
MELBOURNE, Australia and PRINCETON, N.J., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing nove
Opthea Wet AMD Data Featured at Macula Society Meeting
07:00am, Thursday, 06'th Feb 2025
MELBOURNE, Australia, and PRINCETON, N.J., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing nov
Opthea to Host Investor Days in New York and Australia
07:00am, Wednesday, 08'th Jan 2025
Updates on commercial insights and readiness plans for sozinibercept in wet AMD Opthea management to present in New York City on Tuesday, January 28 at 1:30 PM ET In-person events in Sydney on Februar
Opthea to Present at 43rd Annual J.P. Morgan Healthcare Conference
07:00am, Thursday, 19'th Dec 2024
Business update to include masked Phase 3 patient demographics and baseline characteristics Presentation on Wednesday, January 15, 2025, 5:15 PM PT in San Francisco, California MELBOURNE, Australia an
Opthea's Wet AMD Program to be Featured at FLORetina 2024
07:00am, Tuesday, 26'th Nov 2024
MELBOURNE, Australia, and Princeton, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing nov
Opthea Appoints Kathy Connell to Board of Directors
07:00am, Friday, 15'th Nov 2024
Ms. Connell is a commercial executive with business development expertise Appointment takes place as Opthea prepares for Phase 3 wet AMD topline data in 2025 MELBOURNE, Australia, and PRINCETON, N.J.,
Opthea Wet AMD Program to be Presented at Innovate Retina
07:30am, Thursday, 10'th Oct 2024
MELBOURNE, Australia, and Princeton, N.J., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing no
Opthea to Participate in the UBS Virtual Ophthalmology Day 2024
07:30am, Monday, 30'th Sep 2024
MELBOURNE, Australia and PRINCETON, N.J., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing no
